Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis.
Observational studies of the effect of beta-interferon (IFNbeta) on accumulation of fixed disability in relapsing remitting multiple sclerosis (RRMS) in clinical practice have been difficult to interpret due to bias. The aim of this study of 175 RRMS patients was to use Bayesian analysis to establish whether IFNbeta attenuates disability relative to a cohort of matched historical control subjects from the Sylvia Lawry Centre for MS Research. A sensitivity analysis was based on a range of prior probability distributions for IFNbeta efficacy derived from a published meta-analysis of randomised controlled trials (RCTs) of IFNbeta, and the data were interpreted both unmodified and using variance inflation and point estimate bias correction; the corrected data interpreted in the light of the most likely prior probability distribution yielded a 95 % posterior credible interval for the odds ratio of accumulation of fixed disability after two years of IFNbeta therapy of 0.52, 0.94. It is concluded that two years of IFNbeta therapy for RRMS reduces accumulation of fixed disability in clinical practice.
O'Rourke
Killian
K
Department of Neurology, St. Vincent's University Hospital, Dublin 4, Ireland.
Walsh
Cathal
C
Hutchinson
Michael
M
D000293:Adolescent; D000328:Adult; D001499:Bayes Theorem; D016022:Case-Control Studies; D015331:Cohort Studies; D004185:Disability Evaluation; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D015201:Meta-Analysis as Topic; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D019370:Observation; D016017:Odds Ratio; D016032:Randomized Controlled Trials as Topic
D007155:Immunologic Factors; D016899:Interferon-beta
J Natl Cancer Inst. 1996 Nov 20;88(22):1645-51
8931608
Ann Neurol. 1983 Mar;13(3):227-31
6847134
Am J Med. 1982 Feb;72(2):233-40
7058834
Acta Neurol Scand. 2000 Oct;102(4):209-17
11071104
J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):450-7
10727480
Ann Neurol. 2002 Oct;52(4):400-6
12325067
J Neurol. 2005 Jul;252(7):795-800
15772741
Neurology. 1995 Jul;45(7):1277-85
7617182
Ann Neurol. 1996 Mar;39(3):285-94
8602746
Neurology. 2005 Oct 11;65(7):1066-70
16217060
J Neurol Sci. 2001 Aug 15;189(1-2):13-21
11535229
Lancet. 1998 Nov 7;352(9139):1498-504
9820297
BMJ. 1996 Sep 7;313(7057):603-7
8806254
Brain. 1999 Oct;122 ( Pt 10):1941-50
10506095
Mult Scler. 2005 Feb;11(1):46-50
15732266
Lancet. 2004 May 22;363(9422):1728-31
15158638
JAMA. 1994 Jul 13;272(2):125-8
8015122
Mult Scler. 2003 Oct;9(5):451-7
14582768
Neurology. 1983 Nov;33(11):1444-52
6685237
Lancet. 2003 Feb 15;361(9357):545-52
12598138
Arch Intern Med. 1992 Mar;152(3):507-12
1546913
Eur J Neurol. 2003 Nov;10(6):671-6
14641512
Brain. 1989 Dec;112 ( Pt 6):1419-28
2597989
J Neurol Neurosurg Psychiatry. 2003 Dec;74(12):1689-92
14638892
J Neurol Neurosurg Psychiatry. 2003 Jul;74(7):946-9
12810786